Market research
SQZ Sqz Biotechnologies Co
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- 0.0%
- Beta
- 2.71
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US78472W1045
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- 0.0%
- Beta
- 2.71
About
About Sqz Biotechnologies Co
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SQZ discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.
Based on the above factors, SQZ Biotechnologies Company gets an overall score of 1/5.